Eisai R&d Management Co., Ltd.

So Yasui

Richard S Clark

Fumiyoshi Matsuura

Shinsuke Hirota

Tetsuya Kawahara

Jun Niijima

Masanobu Shinoda

Naoki Yoneda

Kazunobu Kira

Hiroshi Azuma

Takao Omae

Ikuo Kushida

Kazutomi Kusano

Hirofumi Kuroda

Daisuke Iida

Yasuaki Kamada

Toshiyuki Ohfusa

Yoko Ito

Atsushi Takemura

Masaki Mikamoto

The present invention provides crystals of (1R,3R,15E,28R,29R,30R,31R,34R,36R,39S,41R)-29,41-Difluoro-34,39-bis(sulfanyl)-2,33,35,38,40,42-hexaoxa-4,6,9,11,13,18,20,22,25,27-decaaza-34&#x3bb;,39&#x3bb;-diphosphaoctacyclo[28.6.4.10.10000]dotetraconta-5,7,9,11,15,19,21,23,25-nonaene-34,39-dione (Compound (I)) ammonium salts, Compound (I) sodium salts, or Compound (I), possessing a potential to be used as drug substance in pharmaceuticals.

Salts of compounds and crystals thereof

The disclosure provides pyrazolo[1,5-a]pyrimidine compounds, and pharmaceutically acceptable salts thereof, having protease-activated receptor 2 (PAR2) inhibitory action, pharmaceutical compositions containing the same, and methods of treatment using the same.

Pyrazolo[1,5-a]pyrimidine compound

By oral administration of a compound represented by the following Formula (I): the blood level of Compound (IV): which has an excellent inhibitory action against blood coagulation factor VIIa and the anticoagulant action, reaches a level sufficient for expression of its pharmacological actions. Therefore, the compound of the present invention is useful as a therapeutic and/or prophylactic agent for diseases caused by thrombus formation. 

Prodrug of triazolone compound

Growing community of inventors

Tsukubamirai, Japan

So Yasui